Summary.-The disappearance rate (k) of i.v. glucose was measured in cachectic and non-cachectic cancer patients and tumour-free controls. The respective k values were found to be 106+027 (mean+s.d.), 164±034 and 163±023. Of the other parameters measured, only plasma albumin level was found to vary significantly amongst the 3 categories, the mean level being the lowest in cachectic cancer patients. The means of total plasma protein, fasting blood glucose and plasma liver enzyme concentrations were similar in the 3 groups. Glucagon, a potent insulin secretogogue, failed to augment the fasting insulin level in cachectic but did so in non-cachectic cancer patients. Taken together, the findings suggest that the reduced glucose tolerance in patients with neoplasia is due to impairment of insulin release exhibited predominantly by ill-nourished advanced cancer patients having a moderate to severe degree of hypoalbuminemia.
GLUCOSE intolerance has long been recognized as a manifestation of cancer (Edwards, 1919) . It has been shown that the impaired glucose tolerance in neoplasia is independent of age, sex and ethnic origin, and it occurs irrespective of the type of tumour (Glicksman and Rawson, 1956) . Tumour-bearing patients, in general, have fasting blood glucose and immunoreactive insulin concentrations similar to those observed in tumour-free controls (Holroyde et al., 1975) even though they have a markedly subnormal disappearance rate of intravenously given glucose (Marks and Bishop, 1956; . The origin of cancer-associated glucose intolerance remains, however, obscure (Glicksman and Rawson, 1956) .
Recent studies on malnourished children (Milner, 1971) , adults (Smith et al., 1975) and animals (Heard, 1966; Weinkove et al., 1976) conclusively demonstrate that malnutrition can lead to glucose intolerance. In particular the work on malnourished animals (Weinkove et al., 1976 ) has implicated protein deficiency as an important precursor of impaired carbohydrate metabolism. For instance, weanling rats fed a protein-deficient diet and challenged with i.v. glucose, showed a markedly reduced rate of disappearance of glucose from the blood, compared with normally fed animals. The mean fasting blood-glucose level of the protein-starved rats was found to be similar to that for the controls. This situation is very like that seen in patients with cancer, and makes one think that glucose intolerance in such patients could be due to a form of protein deficiency. To examine this possibility we have studied both well-nourished and ill-nourished cancer patients with respect to their glucose tolerance and protein status. Glucagon-mediated insulin release.-Glucagon, a hormone which is known to induce release of pre-formed insulin (Grodsky et al., 1967) was used to study the secretory capacity for pancreatic insulin of 5 cachectic and 5 noncachectic cancer patients not included in the glucose-tolerance trial. From each patient a fasting venous-blood sample was initially taken for estimation of insulin using a specific radio-immunoassay (Albano et at., 1972 Tables I and II respectively. The corresponding features of control patients are in Table III. Table IV 
DISCUSSION
The results demonstrate a definite association between impaired glucose tQlerance and cachexia in neoplasia. Cachexia is, in turn, seen to be associated with hypoalbuminemia, a feature which has been observed by several previous workers (Ariel, 1949; Winzler, 1953; Peden et al., 1957) .
Alteration in the functional capacity of the liver (the major site of albumin synthesis) (Madden and Whipple, 1940) does not seem to be responsible for the low levels of circulating albumin observed in neoplastic cachexia (Winzler, 1953) . Our data are consistent with this thesis. Hence, in the absence of any gastrointestinal disturbance, chronic haemorrhage, or sepsis, hypoalbuminemia, in advanced cancer patients, is likely to arise from either increased protein breakdown, excessive utilization of protein by the tumour, reduced protein intake, or a combination of these. Several previous investigations have failed to demonstrate a protein-losing catabolic state in malignant cachexia (Waterhouse et al., 1951; Fenninger and Mider, 1954; Holroyde et al., 1975 (Sherman et al., 1950) . Evidently, protein deprivation in advanced cancer seems to arise not only from anorexia, the major cause of cachexia (Theologides, 1972) but also from monopolization of the host's protein metabolic pool by the tumour tissue (Mider et al., 1948 (Weinkove et al., 1976) . This fact, taken in conjunction with our data on glucagon-mediated insulin release in cachectic cancer patients, suggests a similar underlying mechanism for glucose intolerance in human neoplasia.
From the foregoing discussion and the data presented above, the glucose intolerance exhibited by both cachectic cancer patients and protein-deficient weanling rats, seems to originate from a state of malnutrition due to reduced dietary intake of protein and increased protein demand. Hence, in order to improve the nutritional status of advanced cancer patients it may be necessary not only to increase their dietary intake but at the same time to somehow reduce the metabolic activity of tumour tissue. Failure to achieve these goals simultaneously may explain why, in the past, protein repletion alone has been unsuccessful in treating malignant cachexia, whilst similar treatment of non-malignant cachexia has resulted in a gain in weight and in total circulating albumin (Peden et al., 1957) .
